BioNTech and Triastek have entered a research partnership and platform technology licence agreement focusing on the development of 3D-printed oral RNA therapeutics.
The companies will create RNA therapeutics to be delivered orally, using 3D printing technology.
Go deeper with GlobalData
The collaboration will harness Triastek’s capabilities in new oral tablet designs made possible by 3D printing.
These designs optimise the delivery of RNA therapeutics across the gastrointestinal mucosa, minimise degradation in the gastrointestinal tract and ensure that the therapeutics reach the part of the gastrointestinal tract where absorption is potentially the highest.
Triastek’s capabilities in designing tablet structures with distinct external and internal geometries, including multiple-layer and multi-compartment designs, will be pivotal in optimising the delivery of novel RNA therapeutics.
Triastek is entitled to an upfront payment of $10m, and will receive development, regulatory and commercial milestone payments that could exceed $1.2bn, along with tiered royalties on potential future product sales from BioNTech.
Triastek founder and CEO Dr Senping Cheng stated: “We are immensely honoured to announce our collaboration with BioNTech, a leader in revolutionising patient care with transformative medicines.
“We believe this collaboration stands as a promising milestone in advancing oral RNA therapeutics using 3D printing technology and aims to set new benchmarks in the development of large molecule oral drugs. We are committed to working diligently together to make breakthroughs in oral delivery of RNA therapeutics.”
In May 2024, BioNTech announced an expansion of its strategic partnership with the Coalition for Epidemic Preparedness Innovations, aiming to strengthen the mRNA vaccine ecosystem in Africa.
